Clinical Trial to Evaluate AB011 Injection in Patients With CLDN18.2-positive Advanced Solid Tumors

  • STATUS
    Recruiting
  • participants needed
    103
  • sponsor
    Carsgen Therapeutics, Ltd.
Send
Updated on 19 February 2024
See if I qualify
solid tumour
treatment regimen
solid neoplasm

Summary

This is an open, two-stage, phase I study to evaluate the safety, tolerability, pharmacokinetics and preliminary efficacy of AB011 injection in patients with CLDN18.2-positive advanced solid tumors.

Description

This study is an open, two-stage, phase I study to evaluate the safety, tolerability, pharmacokinetics and preliminary efficacy of AB011 injection in patients with CLDN18.2-positive advanced solid tumors. The study is composed of two stages: stage I is for dose escalation and stage II is for dose expansion.

Details
Condition Gastropathy, stomach discomfort, Gastric Cancer, Gastric Cancer, stomach cancer, Solid Tumor, Pancreatic Adenocarcinoma, stomach cancer, stomach discomfort
Age 18-80 years
Treatment AB011 Injection
Clinical Study IdentifierNCT04400383
SponsorCarsgen Therapeutics, Ltd.
Last Modified on19 February 2024

Eligibility

 Yes No Not Sure

Inclusion Criteria

\. Aged 18 to 80 years, either sex
\. Patients with histologically or pathologically confirmed advanced solid tumors should have failed the standard treatment, or have no standard treatment regimen available, or have no access to standard treatment
\. Tumor tissue samples is CLDN18.2 positive detected by central laboratory
\. According to RECIST1.1, there are at least one evaluable tumor lesion during dose escalation period (period 1), and at least one measurable tumor lesion during dose expansion period (period 2)
\. The ECOG score is 0 to 1
\. Expected survival > 3 months
\. Various organs in good condition
\. Fertile eligible patients (male and female) and their partners are willing to use a reliable method of contraception (hormones, barriers or abstinence) during the study and within 90 days after the last study treatment; women of childbearing potential must be tested for serum or urine pregnancy within 7 days before enrollment with negative results
\. Patients are informed of this study before the trial and sign written informed consent form

Exclusion Criteria

\. Received anti-tumor therapies within 4 weeks prior to first administration of study drug, except: within 6 weeks for nitrosoureas or mitomycin C, within 2 weeks or 5 half-life of drugs (whichever longer) for oral fluorouracils and small molecular targeted drugs, and within 2 weeks for traditional Chinese medicines with indications of anti-tumor
\. Received other non-marketed clinical trial drugs within 4 weeks prior to first administration of study drugs
\. Received major surgery or had significant trauma within 4 weeks prior to first administration of study drug
\. Received systemic corticosteroids or other immunosuppressors within 14 days prior to first administration of study drug
\. Patients with AEs from previous treatment that have not recovered to CTCAE 5.0 1
\. Patients have central nervous system (CNS) metastasis or meningeal metastasis, or other evidences which demonstrate the CNS metastasis or meningeal metastasis are not controlled, resulting that patients are not eligible for enrollment at the investigator's discretion
\. Patients with any active infection which requires systemic treatment with of anti-infection currently
\. Patients with medical history of immune deficiency
\. Patients with hepatitis B; with HCV infection
\. Patients have interstitial lung disease at present, or had medical history of interstitial lung disease
\. Patients have significant medical history of cardiovascular and cerebrovascular diseases
\. Have high risks of gastrointestinal hemorrhage at the investigator's discretion
\. Patients who need long-term use of non-steroidal anti-inflammatory drugs (NSAIDs)
\. Known alcohol use or drug dependence
\. Patients with mental disorders or poor compliance
\. Pregnant or lactating women
\. Patients have other serious systemic diseases or cannot participate in this trial due to other reasons, at the investigator's discretion
Clear my responses
Read more

How to participate?

Step 1 Connect with a study center
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer  to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact

site

Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider

Browse trials for

solid tumour
treatment regimen
solid neoplasm

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name
Edit Delete

Added by • 

 • 

Private

Edit Delete

Reply by • • Private
Edit Delete

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note
  • abc Select a piece of text.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.